Rifabutin Loaded Biogenic Silver Nanoparticles: Development, Characterization, and Evaluation of Antidiabetic Activity in Streptozotocin Induced Diabetic Rats
TL;DR
The superior therapeutic efficacy of Rifabutin‐AgNPs over pure rifabutin highlights the potential of this green synthesized nanoformulation as an efficient platform for diabetes management at the chemical biological interface.
Abstract
Diabetes mellitus characterizes a key universal health concern associated with severe metabolic complications. In this current study, a biogenic approach was employed to synthesize silver nanoparticles (AgNPs) using rifabutin as both a reducing and stabilizing agent. The resulting Rifabutin‐AgNPs were thoroughly characterized by UV–vis spectroscopy, x‐ray diffraction (XRD), scanning electron microscopy (SEM), and Fourier‐transform infrared spectroscopy (FTIR), confirming their crystalline nature and functional group interactions responsible for nanoparticle stabilization. The antidiabetic potential of the synthesized Rifabutin‐AgNPs was evaluated in streptozotocin (STZ)‐induced diabetic rats. Oral administration of Rifabutin‐AgNPs (5 and 10 mg/kg) for 14 days produced a significant, dose‐dependent reduction in blood glucose levels, improved serum lipid profiles, and normalized hepatic transaminase (SGOT and SGPT) activities compared with untreated diabetic controls. The superior therapeutic efficacy of Rifabutin‐AgNPs over pure rifabutin highlights the potential of this green synthesized nanoformulation as an efficient platform for diabetes management at the chemical biological interface.